Dr. Tracy Beth Høeg, the acting head of the Food and Drug Administration’s drug center responsible for regulating prescription and over-the-counter medications, is leaving the agency, according to senior FDA confirmation reported by CBS News and STAT. The departures add to a period of leadership turnover at the FDA. STAT reports that Høeg’s exit comes days after FDA Commissioner Marty Makary submitted his resignation. CBS describes Høeg’s departure as another in a series of personnel moves at the agency, occurring as the FDA faces uncertainty about interim leadership. Both outlets frame the change primarily as a staffing and leadership development, with the focus on who is exiting rather than on specific policy shifts or regulatory changes. As Høeg’s role is described as acting, her departure raises questions about who will oversee the drug center function next and how the FDA will manage leadership during the transition.